m+Medelevator.RU
← Поиск публикаций
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2014

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Consensus StatementСтатьяКлинические рекомендацииОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Broadley Simon A, Barnett Michael H, Boggild Mike, Brew Bruce J, Butzkueven Helmut, Heard Robert, Hodgkinson Suzanne, Kermode Allan G, Lechner-Scott Jeannette, Macdonell Richard A L, Marriott Mark, Mason Deborah F, Parratt John, Reddel Stephen W, Shaw Cameron P, Slee Mark, Spies Judith, Taylor Bruce V, Carroll William M, Kilpatrick Trevor J, King John, McCombe Pamela A, Pollard John D, Willoughby Ernest, MS Neurology Group of the Australian and New Zealand Association of Neurologists

Аннотация

Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты